Sana Biotechnology (NasdaqGS:SANA) FY Conference Transcript

Summary of Sana Biotechnology FY Conference Call Company Overview - Company: Sana Biotechnology (NasdaqGS:SANA) - Focus: Developing engineered cells as medicines, specifically targeting type 1 diabetes and allogeneic CAR-T therapies [2][19] Key Platforms - HypoImmune Platform: Aims to overcome allogeneic rejection of cells by modifying immune response through gene editing [2][3] - Fusogen Platform: A cell-specific in vivo delivery system designed to deliver genetic material directly to target cells without lymphodepletion [16][17] Type 1 Diabetes Focus - Unmet Need: Approximately 9 million people suffer from type 1 diabetes, with significant health risks and no meaningful change in standard care for over 100 years [5][6] - Clinical Data: Recent proof of concept study published in The New England Journal of Medicine shows promising results for HypoImmune-modified islet cell therapy, with patients producing insulin for the first time in over 30 years [10][19] - Study Design: Cadaveric islets were genetically modified and transplanted without immunosuppression, achieving all primary and secondary endpoints [9][10] Clinical Results - C-peptide Levels: Patients showed stable C-peptide levels, indicating insulin production, with significant improvement in response to meals over six months [10][11] - Immune Evasion: HypoImmune-modified islets demonstrated survival against pre-existing immune responses, with no T cell or antibody recognition [12][14] Allogeneic CAR-T Programs - Programs in Development: - SC291: HypoImmune-modified CD19-directed CAR-T for autoimmune diseases [15] - SC262: CD22-directed allogeneic CAR-T for patients relapsing post-CD19 CAR-T therapy [16] - Clinical Trials: Ongoing studies with expected data release in 2025 [16] Fusogen Platform Development - Lead Product Candidate: SG299, a CD8 targeted fusosome for delivering CD19-directed CAR-T cells, with IND filing expected as early as 2026 [18][19] Conclusion - Progress: Sana Biotechnology is making significant strides in overcoming allogeneic rejection and advancing its CAR-T and Fusogen platforms, with broad applicability across various diseases anticipated [19]